NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.61 -1.02 (-1.23%) GOLD FUTURES
2,303.20 -54.50 (-2.31%) DOW
37,942.99 -443.10 (-1.15%) Bitcoin GBP
48,113.36 -2,061.63 (-4.11%)
VRTX Jun 2024 260.000 call
| Previous close | 172.50 |
| Open | 172.50 |
| Bid | 148.10 |
| Ask | 155.90 |
| Strike | 260.00 |
| Expiry date | 2024-06-21 |
| Day's range | 172.50 - 172.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
